About Iroquois-class homeodomain protein IRX-6
Iroquois-class homeodomain protein IRX-6 (IRX6) is a protein
from Homo sapiens identified by UniProt accession
P78412, 446 residues long.
MolForge cross-references it against 0 known binders and
43 disease associations.
Target properties
| Protein name | Iroquois-class homeodomain protein IRX-6 |
| UniProt accession | P78412 |
| Gene | IRX6 |
| Organism | Homo sapiens |
| Length | 446 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (43)
Diseases linked to this target (Open Targets).
- erythrocyte count · score 0.42
- hematocrit · score 0.40
- hemoglobin measurement · score 0.38
- red blood cell density measurement · score 0.36
- hypospadias · score 0.30
- cutaneous melanoma · score 0.29
- nevus count · score 0.29
- mean corpuscular hemoglobin concentration · score 0.27
- neurodegenerative disease · score 0.22
- adolescent idiopathic scoliosis · score 0.17
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P78412-F1 | alphafold | PREDICTED | 54.53 | — |
Amino-acid sequence (446 residues)
MSFPHFGHPY RGASQFLASA SSSTTCCEST QRSVSDVASG STPAPALCCA PYDSRLLGSA RPELGAALGI YGAPYAAAAA AQSYPGYLPY SPEPPSLYGA LNPQYEFKEA AGSFTSSLAQ PGAYYPYERT LGQYQYERYG AVELSGAGRR KNATRETTST LKAWLNEHRK NPYPTKGEKI MLAIITKMTL TQVSTWFANA RRRLKKENKM TWAPKNKGGE ERKAEGGEED SLGCLTADTK EVTASQEARG LRLSDLEDLE EEEEEEEEAE DEEVVATAGD RLTEFRKGAQ SLPGPCAAAR EGRLERRECG LAAPRFSFND PSGSEEADFL SAETGSPRLT MHYPCLEKPR IWSLAHTATA SAVEGAPPAR PRPRSPECRM IPGQPPASAR RLSVPRDSAC DESSCIPKAF GNPKFALQGL PLNCAPCPRR SEPVVQCQYP SGAEAG
Explore Iroquois-class homeodomain protein IRX-6 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets